SCHEMBL12450862

SCHEMBL12450862

CC(=O)NCC(=O)N1CC[C@@H](Oc2ccccc2)C1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.57
SCD O00767 1/20 0.50
ACACB O00763 1/20 0.47
EPHX2 P34913 2/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2J2 P51589 1/20 0.46
USP30 Q70CQ3 1/20 0.46
CASP1 P29466 1/20 0.46
KDM1A O60341 2/20 0.45
MAOA P21397 2/20 0.45
MAOB P27338 2/20 0.45
MAPT P10636 1/20 0.44
NAMPT P43490 1/20 0.44
RIPK1 Q13546 1/20 0.44
NPC1 O15118 1/20 0.43
GAA P10253 1/20 0.43
RAB9A P51151 1/20 0.43
TACR1 P25103 1/20 0.43
CHRM2 P08172 2/20 0.43
CHRM3 P20309 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15677630 0.83 USP30 (0.50) SCDEPHX2USP30CASP1MAPT
SCHEMBL6123598 0.81 EPHX2 (0.51) ALDH1A1ACACBEPHX2CYP2C9CYP2J2
SCHEMBL12450572 0.81 CCR1 (0.46) ACACBCASP1
SCHEMBL10202990 0.80 CHRM3 (0.50) SCDEPHX2USP30CASP1NAMPT
SCHEMBL12791421 0.79 USP30 (0.53) ACACBEPHX2CYP2C9CYP2J2USP30
SCHEMBL796858 0.78 EPHX2 (0.53) EPHX2CYP2C9CYP2J2USP30RIPK1
SCHEMBL796833 0.78 EPHX2 (0.53) EPHX2CYP2C9CYP2J2USP30RIPK1
SCHEMBL2532124 0.78 EPHX2 (0.53) EPHX2CYP2C9CYP2J2USP30RIPK1
SCHEMBL12442639 0.77 NAMPT (0.57) ALDH1A1EPHX2NAMPTRIPK1
SCHEMBL10608624 0.76 EPHX2 (0.49) EPHX2CYP2C9CYP2J2USP30MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120238749-A1 INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238749-A1 INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME IL1B, IL1A, IL1R1 ALDH1A1 269/4885SCD 454/4885ACACB 410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.